German Center for Neurodegenerative Diseases (DZNE)   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Göttingen Germany (2009)

Organization Overview

First Clinical Trial
2014
NCT02008721
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

German Center for Neurodegenerative Diseases (DZNE)

Active Ingredients

Drugs in Phase 3 Trials (1)

l-epigallocatechin (1 trial)

Drugs in Phase 1 Trials (1)

vorinostat (zolinza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Atrophy (Phase 3)

Multiple System Atrophy (Phase 3)

Shy-Drager Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2